Scarica l'app Stockscreener
62.90
0.13%
-0.08
Dopo l'orario di chiusura:
62.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position - AOL.com
Private Capital Advisors Inc. Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
How Structure Therapeutics Inc. (GPCR) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026 - TradingView
Structure Therapeutics Inc. (GPCR): Analyst Consensus Points To A 60% Upside Potential - DirectorsTalk Interviews
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT) - The Globe and Mail
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake - AOL.com
Structure Therapeutics (GPCR) Gained from Favorable Clinical Data - Finviz
Aberdeen Group plc Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Structure Therapeutics (GPCR) Projected to Post Earnings on Thursday - Defense World
Structure Therapeutics surges on phase 2 data for GLP-1 pill aleniglipron - MSN
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST) - The Globe and Mail
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition? - TradingView
Readystate Asset Management LP Increases Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA) - The Globe and Mail
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Short Interest Down 17.8% in January - MarketBeat
(GPCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
FY2030 Earnings Forecast for GPCR Issued By HC Wainwright - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), CSL (CMXHF) - The Globe and Mail
Structure Therapeutics Inc. Sponsored ADR $GPCR Stake Lessened by Federated Hermes Inc. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD) and Entera Bio (ENTX) - The Globe and Mail
Assessing Structure Therapeutics (GPCR) Valuation As Oral Obesity Drug GSBR-1290 Advances In Phase 2 - Sahm
Principal Financial Group Inc. Decreases Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics’ Oral Obesity Drug Enters Phase 2 As Investor Focus Grows - Sahm
Structure Therapeutics (NASDAQ:GPCR) Shares Down 10.7%Here's Why - MarketBeat
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Pfizer (PFE) and Merck & Company (MRK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Pfizer (PFE) - The Globe and Mail
UPDATE 3-Novo Nordisk warns on profits and sales amid Trump drug price crackdown - Sahm
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Praxis Precision Medicines (PRAX) - The Globe and Mail
Responsive Playbooks and the GPCR Inflection - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Cut to "Sell" at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Viking Therapeutics (VKTX) - The Globe and Mail
CCG Wealth Management LLC Sells 140,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Head to Head Review: Structure Therapeutics (NASDAQ:GPCR) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Genentech Licensing Deal and Guggenheim Reaffirmation Could Be A Game Changer For Structure Therapeutics (GPCR) - Sahm
Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It - Benzinga
Structure Therapeutics (NASDAQ:GPCR) Raised to "Strong-Buy" at The Goldman Sachs Group - MarketBeat
Understanding the Setup: (GPCR) and Scalable Risk - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Assessing Structure Therapeutics (GPCR) Valuation After Genentech Deal And Growing Obesity Pipeline Confidence - Sahm
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s - CNBC
Goldman Sachs Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $102 - 富途资讯
Why Structure Therapeutics Stock Is Breaking Out Now - TipRanks
Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Short Interest in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Grows By 23.7% - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
SG Americas Securities LLC Has $1.11 Million Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Atea Pharmaceuticals (AVIR) and Penumbra (PEN) - The Globe and Mail
Jim Cramer on Structure Therapeutics: "I Don't Want to Touch It" - Finviz
Structure Therapeutics (GPCR) Is Up 26.9% After Strong Obesity Pill Data And $748 Million OfferingWhat's Changed - Sahm
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpShould You Buy? - MarketBeat
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Finviz
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Glaukos (GKOS) - The Globe and Mail
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why - Finviz
2.90%
2.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):